Skip to Main Content
Lantern_Icon_blue
Lantern by Labaton
Link_Arrow
ClientConnect_Icon_blue
Client Connect
Link_Arrow
Labaton Logo
  • The Firm
  • Practices
  • Our Team
  • Cases
  • News & Insights
  • Client Services
  • Careers
Contact Us
Established 1963

Back to Resolved Cases
Practice Area: Securities Litigation
Updated: December 21, 2023

Boston Retirement System v. Alexion Pharmaceuticals Inc.

Case Materials

Consolidated Complaint
Claim Form
Notice of Settlement
Stipulation of Settlement
Final Approval Brief
Fee Brief
Joint Declaration of Gregg G. Levin and Michael H. Rogers ISO Final Approval and Attorneys' Fees and Expenses
Order Approving Plan of Allocation
Order Awarding Attorneys' Fees and Expenses
Final Order and Judgment

Labaton Keller Sucharow is co-lead counsel in a securities class action lawsuit against Alexion Pharmaceuticals, Inc. (Alexion) and certain of its executives. A $125 million settlement was reached that resolves claims on behalf of all persons or entities who purchased or otherwise acquired the publicly traded common stock of Alexion from January 30, 2014, to May 26, 2017, inclusive (the Class Period), and were allegedly damaged thereby.

Alexion is a pharmaceutical drug company that, during the Class Period, generated nearly all of its revenue from selling the Company’s flagship drug, Soliris, which treats, among others, patients suffering from one of two ultra-rare diseases. In the action, Class Representatives alleged that Defendants violated the Securities Exchange Act of 1934 by allegedly making materially false and misleading statements and omissions principally connected to Alexion’s sales practices in connection with the marketing of Soliris. Class Representatives further alleged that the price of Alexion common stock was artificially inflated as a result of the allegedly false and misleading statements and omissions and that the Company’s stock price declined when the alleged truth about Alexion’s business was allegedly revealed through a series of partial corrective disclosures beginning with information released on November 4, 2016, which allegedly affected the price of Alexion common stock on November 7, 2016, and thereafter.

The case is Boston Retirement System v. Alexion Pharmaceuticals, Inc., Case No. 3:16-cv-02127 (AWT). Labaton Keller Sucharow represents co-lead plaintiff Public Employee Retirement System of Idaho. The Court in charge of the case is the United States District Court for the District of Connecticut.

Submit Claim Form

If you purchased or otherwise acquired the publicly traded common stock of Alexion from January 30, 2014, to May 26, 2017, inclusive, and were allegedly damaged thereby, you may be entitled to a payment from a class action settlement. To be eligible for a payment, you must submit a Claim Form to the Claims Administrator by December 15, 2023.

Settlement Hearing

A Settlement Hearing was held on December 20, 2023, at the Abraham Ribicoff Federal Building, United States Courthouse, South Courtroom, 450 Main Street, Hartford, CT 06103. The Court approved the Settlement and the Plan of Allocation and awarded attorneys’ fees and expenses. If you have questions about the Settlement, please contact Labaton Keller Sucharow at settlementquestions@labaton.com; 1-888-219-6877; or contact the Claims Administrator, at 1-866-573-1726.

Additional information about the Settlement can also be found at www.AlexionSecuritiesSettlement.com.

logo

Our Locations

New York

140 Broadway
New York, NY 10005
Tel: +1 212.907.0700

Delaware

222 Delaware Avenue, Suite 1510
Wilmington, DE 19801
Tel: +1 302.573.2540

London

1 King William Street
London, EC4N 7AF United Kingdom
Tel: +44 20 3582 0981

Washington, D.C.

1050 Connecticut Avenue NW, Suite 500
Washington, D.C. 20036
Tel: +1 202.772.1881

Useful Links

  • Practices
  • Cases
  • News & Insights
  • Client Services
  • Contact

The Firm

  • Our Team
  • Our Story
  • Awards & Accolades
  • Offices
  • Social Commitment
  • Careers for Attorneys
  • Careers for Business Professionals
  • Attorney Development

Stay Connected

fbfb
Facebook
Xx
Twitter / X
inin
LinkedIn
Footer_Graphic
© Labaton Keller Sucharow LLP All Rights Reserved 2026
Attorney Advertising DisclaimerPrivacy PolicyCookie PolicyCalifornia Privacy Policy and Notice of Collection of Personal InformationTransparency in Coverage Rule